Mumps Management, Follow Up And Prevention

Malaysia
Search
Sign In

Paediatrics Search

Paediatrics

Paediatrics

Home News Diseases Conferences Special Reports Multimedia

MUMPS

Mumps is a self-limited viral disease characterized by nonsuppurative swelling and tenderness of one or both parotid glands.
It commonly affects the children aged 2-12 years and very uncommon in <1 year of age.
It is caused by a single-stranded RNA virus classified under Paramyxoviridae family or mumps virus.
Transmission is through airborne droplets from respiratory secretion of infected persons.
Incubation period is typically 14-21 days.

Management

Prevention

Mumps Vaccine

Available as a single-antigen preparation or combined w/ other vaccines [eg mumps & rubella (MMR), or also w/ varicella (MMRV)]
- Single-antigen is not routinely recommended
- Based on several studies, a single dose of MMR is 75-91% effective while vaccine effectiveness of 88% is seen w/ 2 doses
- MMRV is approved for use in healthy children 1-12 yrs of age

Single-antigen (MMR) is indicated for children ≥1 yr of age w/ low risk for mumps exposure
Second-dose MMR is indicated for children 4-6 yr of age at high risk for mumps exposure
Second dose should be given >1 mth after the 1st dose

Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!

Pharmacists’ town hall with Ministry of Health: Preliminary highlights

Rachel Soon, 5 days ago

On 8 August, the first town hall held by the Ministry of Health (MOH) with members of the pharmacy profession took place in Putrajaya. Over 500 pharmacists from across the country and from different areas of practice—community and hospital, public and private, academy and industry—converged to fill the auditorium for the chance to engage in direct dialogue with MOH.

Early rhBNP application lessens severity of reperfusion injury in PCI-treated STEMI patients

Stephen Padilla, 14 Aug 2019

Early administration of recombinant human B-type natriuretic peptide (rhBNP) can lower the incidence of reperfusion injury for patients with ST-elevation myocardial infarction (STEMI) who are receiving percutaneous coronary intervention (PCI) treatment, according to a China study.

Prophylactic methylprednisolone may benefit some neonates undergoing cardiac surgery

11 Aug 2019

Intraoperative methylprednisolone does not appear to significantly prevent the incidence of death, cardiac arrest and other injuries in neonates undergoing cardiac surgery with cardiopulmonary bypass, according to a recent study.